WO2013155528A3 - Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides - Google Patents

Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides Download PDF

Info

Publication number
WO2013155528A3
WO2013155528A3 PCT/US2013/036639 US2013036639W WO2013155528A3 WO 2013155528 A3 WO2013155528 A3 WO 2013155528A3 US 2013036639 W US2013036639 W US 2013036639W WO 2013155528 A3 WO2013155528 A3 WO 2013155528A3
Authority
WO
WIPO (PCT)
Prior art keywords
reducing
formula
methods
insulin sensitivity
increasing insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/036639
Other languages
English (en)
Other versions
WO2013155528A2 (fr
Inventor
Joseph William MCFADDEN
Gabriele Valeria RONNETT
Susan Aja SLOAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FASgen Inc
Original Assignee
FASgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FASgen Inc filed Critical FASgen Inc
Publication of WO2013155528A2 publication Critical patent/WO2013155528A2/fr
Publication of WO2013155528A3 publication Critical patent/WO2013155528A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides chez un sujet, méthodes faisant appel à l'administration d'un ou plusieurs composés de formule I et/ou II.
PCT/US2013/036639 2012-04-13 2013-04-15 Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides Ceased WO2013155528A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623896P 2012-04-13 2012-04-13
US61/623,896 2012-04-13

Publications (2)

Publication Number Publication Date
WO2013155528A2 WO2013155528A2 (fr) 2013-10-17
WO2013155528A3 true WO2013155528A3 (fr) 2013-12-05

Family

ID=49328292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/036639 Ceased WO2013155528A2 (fr) 2012-04-13 2013-04-15 Méthodes de réduction de l'inflammation cérébrale, de renforcement de la sensibilité à l'insuline et de réduction des taux de céramides

Country Status (1)

Country Link
WO (1) WO2013155528A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160231334A1 (en) * 2013-10-28 2016-08-11 The Forsyth Institute Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases
BR112016014180A2 (pt) 2013-12-18 2017-09-26 Astex Therapeutics Ltd reguladores de nrf2
KR101705253B1 (ko) * 2014-10-06 2017-02-22 울산과학기술원 세룰레닌 또는 세룰레닌 유도체를 유효성분으로 함유하는 염증 질환 예방 또는 치료용 약학 조성물
CA2968288A1 (fr) 2014-11-20 2016-05-26 Vib Vzw Compositions et methodes pour le traitement de la maladie de parkinson precoce
PH12017502255B1 (en) 2015-06-15 2022-07-22 Astex Therapeutics Ltd Nrf2 regulators
KR20180018684A (ko) 2015-06-15 2018-02-21 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
EP3359532A1 (fr) 2015-10-06 2018-08-15 GlaxoSmithKline Intellectual Property Development Limited Biaryl pyrazoles utilisés comme régulateurs de nrf2
JP2024534799A (ja) * 2021-08-20 2024-09-26 エナンタ ファーマシューティカルズ インコーポレイテッド １７－ベータ－ヒドロキシステロイドデヒドロゲナーゼ１３型阻害剤及びその使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033506A1 (en) * 2001-11-30 2004-02-19 Dennis Farrelly Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
US20050106217A1 (en) * 2002-02-08 2005-05-19 Johns Hopkins University Licensing And Technology Development Stimulation of CPT-1 as a means to reduce weight
US20110274654A1 (en) * 2010-05-05 2011-11-10 Bahadoor Adilah Triazoles as inhibitors of fatty acid synthase
US20120083471A1 (en) * 2008-07-07 2012-04-05 Townsend Craig A Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033506A1 (en) * 2001-11-30 2004-02-19 Dennis Farrelly Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
US20050106217A1 (en) * 2002-02-08 2005-05-19 Johns Hopkins University Licensing And Technology Development Stimulation of CPT-1 as a means to reduce weight
US20120083471A1 (en) * 2008-07-07 2012-04-05 Townsend Craig A Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same
US20110274654A1 (en) * 2010-05-05 2011-11-10 Bahadoor Adilah Triazoles as inhibitors of fatty acid synthase

Also Published As

Publication number Publication date
WO2013155528A2 (fr) 2013-10-17

Similar Documents

Publication Publication Date Title
JP2012107034A5 (fr)
BR112014031806A8 (pt) método para tratamento de câncer positivo para gd2
EP3143997A3 (fr) Procedes d'administration d'une therapie par le pirfenidone
EP3682875A3 (fr) Méthodes de traitement du syndrome métabolique pédiatrique
ZA201503110B (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2013170068A3 (fr) Modulateurs du transport nucléaire et leurs utilisations
WO2012149299A3 (fr) Procédés de traitement du cancer et de maladies inflammatoires au moyen de céréblon en tant que prédicteur
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
WO2013028818A8 (fr) Composés de pyrimido-pyridazinone et leurs procédés d'utilisation
MX2015011359A (es) Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2014160281A3 (fr) Procédé pour améliorer l'administration de composés thérapeutiques à l'œil
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
EP3013219A4 (fr) Traitement de l'hypoglycémie pour les personnes souffrant de diabète
PH12014502071A1 (en) Beta-hydroxy-beta-methylbutyric acid for imrpoving glucose tolerance
BR112014032169A2 (pt) tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa
HK1222328A1 (zh) 作爲感染性疾病和腸道炎症的藥物靶標的穿孔蛋白-2活化劑和抑制劑
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
WO2013111013A3 (fr) Méthodes de traitement de la maladie d'alzheimer par l'administration de certains composés synthétiques
WO2013090319A3 (fr) Traitement du diabète de type i et de type ii
WO2012145234A3 (fr) Dérivés cyclopropylés et leurs procédés d'utilisation
WO2015079415A9 (fr) Dispersion solide de cobicistat amorphe
WO2014147578A3 (fr) Composés antibactériens contre des bactéries résistantes aux médicaments
WO2011161295A3 (fr) Utilisation de composés anticalcineurine pour le traitement de pathologies associées à une néovascularisation oculaire
MX2016003347A (es) Uso de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio o una sal farmaceuticamente aceptable del mismo en la prevencion y tratamiento de diabetes.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13775534

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/03/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13775534

Country of ref document: EP

Kind code of ref document: A2